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The distinction between metastatic adenocarcinomas of lung
(LAC), breast (BAC), and ovary (OAC) in serous effusions can
be very difficult since they all can present as tight cell clusters.
This is particularly challenging when the malignant effusion is
the patient’s initial presentation or when the patient has a his-
tory of more than one primary. The aim of this study is to evalu-
ate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and
CA125 antibodies in the differential diagnosis of metastatic ade-
nocarcinoma from the lung, breast and ovary in serous effu-
sions.
Forty-six samples of serous effusions with their corresponding
cell blocks were retrieved from our hospital computer system,
including 13 BACs, 13 LACs, and 20 OACs. The diagnoses were
confirmed by the surgical resection. Formalin-fixed and paraffin-
embedded cell block sections were immunostained for WT1,
mCEA, TTF1, and CA125. Two observers blindly reviewed the
immunostained slides without knowledge of the previous clinical
or histologic diagnoses. The staining intensity was graded semi-
quantitatively as negative, 0; weak, 1þ; moderate, 2þ; and
strong, 3þ. The percentage of positively staining cells was esti-
mated. The distribution patterns of reactivity for WT1 and TTF1
were recorded as nuclear, and mCEA and CA125 as membra-
nous stain.
Metastatic OACs showed positive immunoreactivity to WT1 in
19/20 (95%) cases, CA125 in 20/20 (100%), and all showed
negative reaction for both mCEA (0/20, 0%) and TTF1 (0/20,
0%). BAC showed positive reaction in 6/13 (46%) cases to
CA125 and mCEA. Staining pattern was diffuse for CA125 and
focal for mCEA. Only 2/13 (15%) were positive for WT1, while
all of 13 BAC cases (0/13, 0%) were negative for TTF1. LAC
showed positive immunoreactivity for TTF1 in 9/13 (69%) with
a characteristic nuclear staining pattern, but only 3/13 (23%)
were focally stained for WT1. In addition, 8/13 (62%) of LAC
cases were positive for both CA125 and mCEA.
Our results demonstrate that the WT1 stain is specific for met-
astatic carcinoma of ovarian primary, showing a high sensitiv-
ity. In addition, CA125 stain is very sensitive for OACs, but
could be positive in about a half of LAC and BAC cases. An im-
munostaining pattern of positive mCEA as well as negative WT1
rules out OACs, raising the possibility of LACs and BACs. A
positive TTF1 staining supports the diagnosis of metastatic
carcinoma originating from lung rather than breast, while a
negative TTF1 favors the diagnosis of a breast primary. Immu-
nohistochemical studies with WT1, TTF1, and mCEA antibodies
are useful in the differential diagnosis of metastatic adenocarci-
nomas of lung, breast, and ovary. Diagn. Cytopathol. 2007;
35:370–375. ' 2007 Wiley-Liss, Inc.
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Introduction
Malignant serous effusion is not an uncommon clinical
manifestation of adenocarcinoma.1,2 The distinction
between metastatic adenocarcinomas of lung (LAC),
breast (BAC), and ovary (OAC) in serous effusions could
be very difficult or sometimes impossible on the basis of
morphology alone.1–3 This is particularly challenging
when the malignant effusion is the patient’s initial presentation
or when the patient has a history of more than one
primary. However, elucidating the origin of these malig-
nant neoplasms often may have therapeutic consequences
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for the patient.4 Many antibodies directed against specific
cell type antigens have been used in LAC, BAC, and
OAC on the histological section and/or serous effusions
to enhance the pathological diagnosis, with varying
degrees of efficacy but the optimum panel of antibodies is
yet to be reported. When used in specific panels, immuno-
histochemical studies can be extremely useful for deter-
mining tumor type, particularly in cases with an unknown
primary site.5–8
WT1, a tumor suppressor gene initially identified as
contributing to the development of Wilms tumor, is
expressed preferentially in the urogenital system and mes-
oderm-derived tissues.9,10 Relatively specific reactivity for
WT1 protein has been shown in ovarian papillary serous
carcinoma and in a number of different carcinomas in
addition to mesothelioma, desmoplastic small round cell
tumor, and Wilms tumor.11–13
There are no specific markers of ovarian adenocarci-
noma, one of the most common neoplasms to present
with ascites. Antibodies such as CA125 and human alveo-
lar macrophage (HAM) 56 have been proposed as useful
markers of ovarian adenocarcinoma, but immunoreactivity
is often present in adenocarcinomas of other sites, limit-
ing their diagnostic value.12,14,15
Thyroid transcription factor1 (TTF-1) has been
described as a marker that reportedly recognizes carcino-
mas of pulmonary origin, particularly pulmonary adeno-
carcinoma.16–18 TTF-1 is also expressed in the thyroid
gland, the diencephalon, and the bronchioalveolar epithe-
lium.18–21
Monoclonal carcinoembryonic antigens (mCEA) are of
value in confirmation of an adenocarcinoma, as they are
commonly positive in these neoplasms but rarely so in re-
active mesothelial cells or mesothelioma.15,22 However,
certain adenocarcinomas, especially ovarian serous adeno-
carcinomas, are characteristically negative with mCEA.15
The aim of this study was to evaluate the usefulness of
WT1, monoclonal CEA (mCEA), TTF1, and CA125 anti-
bodies as markers in the differential diagnosis of ovarian,
lung, and breast metastatic adenocarcinomas in cytologic
material prepared from malignant effusion specimens.
Materials and Methods
A total of 46 cases of serous effusions were retrieved
from our hospital computer system, including 13 BACs,
13 LACs, and 20 OACs. The diagnosis of each case was
confirmed by surgical excision and histologic examination
of the primary tumor. Formalin-fixed and paraffin-embed-
ded cell block sections from the serous effusions were
stained with hematoxylin and eosin to evaluate the presence
of tumor cells in each cell block. Immunohistochemical
staining was performed on the DAKO Autostainer
(DAKO, Carpinteria, CA) using DAKO LSABþ and 3,30-
diaminobenzidine as the chromogen. Deparaffinized sec-
tions of formalin-fixed tissue at 4-lm thickness were
stained with H&E or labeled with anti-WT1 (1:50; Cell
Marque, Hot Springs, AR), anti-TTF1 (1:200; DAKO
Cytomation, Carpinteria, CA), anti-mCEA (1:1; Cell
Marque), and anti-CA125 (1:100; Vector Laboratories,
Newcastle upon Tyne, UK) along with positive and nega-
tive controls. Citrate antigen retrieval (20 min) was used
before incubation with antibodies. An appropriate positive
control slide for each marker evaluated was included in
each run. Control slides substituting tris buffer for pri-
mary antibody were run as negative controls. Two observ-
ers (WZ & CWM) blindly reviewed the immunostaining
without knowledge of the previous clinical or histopatho-
logic diagnoses. At least 200 cells were counted and the
extent of staining was assessed as percentage of neoplas-
tic cells, and intensity of staining was graded on a 0 to
3þ scale semiquantitatively (negative, 0; weak, 1þ; mod-
erate, 2þ; strong, 3þ). The distribution pattern of immu-
noreactivity for WT1 and TTF1 was recorded as nuclear,
and mCEA and CA125 as membranous staining.
Results
Immunoreactivity for WT1, CA125, TTF1, and mCEA
was studied in a total of 46 cases of metastatic adenocar-
cinoma in cell blocks prepared from serous effusions,
including 13 BACs, 13 LACs, and 20 OACs. Overall
results are summarized in Table I.
WT1
WT1 immunoreactivity was detected in 19/20 (95%)
OCA cases, exhibiting an immunoreactivity in at least
56.6% of neoplastic cells (Fig. C-1). In comparison, only
3/13 (23%) LAC and 2/13 BAC (15%) cases displayed a
WT1 immunoreactivity in 40.7% and 40.0% of neoplastic
cells, respectively. WT1 immunoreactivity demonstrated a
strong nuclear staining pattern, showing an average inten-
sity of 2.67 in LCA, 2.58 in OAC, and 2.5 in BAC neo-
plastic cells.
CA125
CA125 immunoreactivity was detected in 20/20 (100%)
OAC cases, demonstrating the characteristic membranous
staining pattern in 92.3% of neoplastic cells, rimming
Table I. Immunoreactivity for WT1, CA125, TTF1 and mCEA in
Malignant Effusions of Ovary, Lung, and Breast Adenocarcinomas














Ovary 20 19 (95) 20 (100) 0 (0) 0 (0)
Lung 13 3 (23) 8 (62) 9 (69) 8 (62)
Breast 13 2 (15) 6 (46) 0 (0) 6 (46)
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Figs. C-1–C-5. Fig. C-1. Strong nuclear immunoreaction for WT-1 in a metastatic ovarian adenocarcinoma, 3600. Fig. C-2. Strong membranous
immunoreaction to CA125 in a metastatic ovarian adenocarcinoma, 3400. Fig. C-3. Moderate nuclear immunoreaction to TTF-1 in a metastatic lung
adenocarcinoma, 3600. Fig. C-4. Moderate membranous staining to mCEA detected in metastatic lung adenocarcinoma, 3600. Fig. C-5. Moderate
membranous immunoreaction to mCEA in a metastatic breast adenocarcinoma, 3400.
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around the tumor cell aggregates (Fig. C-2). CA125 was
positive in 8/13 (62%) LAC and 6/13 (46%) BAC cases,
with a similar staining pattern as the tumor cells in ovary.
In the positively staining lung and breast cases, about 70.6%
and 90% neoplastic cells were stained with CA125,
respectively. Although OAC showed a uniformly 3þ
staining, there is no significant difference in the staining
intensity in comparison with LAC (2.88) and BAC (2.83)
cases.
TTF1
TTF1 immunoreactivity was detected in 9/13 (69%) LAC
with the characteristic nuclear staining pattern and an av-
erage of 2.0 intensity (Fig. C-3). No nuclear immunostain-
ing was detected in either the OAC (0/20, 0%) or BAC
cases (0/13, 0%).
mCEA
mCEA immunoreactivity with a membranous staining pat-
tern was detected in 8/13 (62%) LAC and in 6/13 (46%)
BAC cases (Figs. C-4 and C-5). The average staining in-
tensity was 2.75 for both LAC and 2.67 for BAC. In con-
trast, there is negative immunoreaction with mCEA for all
20 OAC cases.
Discussion
Serous effusions may be the first symptom of both meso-
theliomas and metastatic adenocarcinomas. In these cir-
cumstances, cytology can play a critical role in the diag-
nosis. The initial challenge is to distinguish the malignant
mesothelioma (MM) from metastatic adenocarcinoma in
cytologic specimens, which is aided greatly by the use of
a panel of antibody immunocytochemistry.1–8 The next
challenge is to identify the primary neoplasm in the case
of adenocarcinoma manifesting initially as an effusion or
if the patient has a history of more than one primary. In
this study, we evaluated the usefulness of WT1, monoclo-
nal CEA (mCEA), TTF1, and CA125 antibodies in the
differential diagnosis of metastatic LAC, BAC, and OAC
in serous effusions.
WT1 is a tumor suppressor gene implicated in the de-
velopment of Wilms tumor and has been demonstrated in
a high percentage of OAC and in some BAC.11–13 The
frequent expression of WT1 in ovarian serous and transi-
tional cell carcinomas, and its infrequent expression in
other ovarian carcinoma subtypes, such as clear cell,
mucinous, and endometrioid adenocarcinomas, has been
well documented.10 Our study demonstrates that WT-1 is
a highly sensitive marker of OAC and its expression is
only seen in a small fraction of lung and breast carcino-
mas (23 and 15%, respectively). However, there was no
significant difference noted in the intensity and the
percentage of stained neoplastic cells in any of the immu-
noreactive BAC and LAC cases when compared with
OAC. These results are in agreement with previous
studies.9–13,15,18 In addition to being a sensitive marker of
ovarian serous carcinomas in the workup of carcinoma of
unknown primary, WT-1 is also a relatively specific ovar-
ian marker. We believe that WT-1 should be included in
the immunostaining panel of malignant effusions of
unknown primary and that a negative reaction would
argue strongly against the diagnosis of OAC.
Overall, 69% of primary pulmonary adenocarcinomas
showed staining for TTF-1, and no immunoreactivity was
noted in ovarian and breast carcinomas. TTF1 immunostain-
ing was characterized by a nuclear pattern in 69% of tumor
Fig. 1. Proposed application of antibody panel in the differential diagnosis of ovarian, lung, and breast adenocarcinoma. Asterisk indicates that lung ad-
enocarcinoma usually reacts more diffusely with CA125, while breast tends to be focally reactive.
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cells, with a moderate intensity (2.0). Our data are very
close to the findings of several previous reports, where the
range of positive reaction was 72–80%, and is also consist-
ent with the almost universal finding that anti-TTF-1 only
stains adenocarcinomas that are primary in the lung and thy-
roid gland.16–22 The usefulness of TTF-1 as a marker of
pulmonary adenocarcinoma diagnosis is confirmed by our
study, although it is limited by the sensitivity of TTF1 stain-
ing.16,17 TTF-1 is the best marker to confirm the diagnosis
of LAC; however, a negative TTF-1 expression does not
rule out a lung primary and a panel of antibodies will be an
important part in determining the primary site.
CEA is a glycoprotein within a large family of glyco-
proteins, which is expressed in adenocarcinomas in a
variable percentage, depending on the monoclonal or
polyclonal antibodies. The percentage of carcinomas posi-
tive for CEA is variable, depending on the primary site
and the subtype of carcinoma.15,22 Our study demon-
strated that a membranous mCEA expression pattern was
found in 8/12 (67%) LAC and 6/13 (46%) BAC, but no
mCEA immunoreactivity was detected in OAC. This find-
ing supports the value of monoclonal carcinoembryonic
antigen (mCEA) in the differential diagnosis as it is com-
monly positive in breast and lung carcinomas, while char-
acteristically negative in ovarian serous adenocarcinoma.
Therefore, CEA is one of the best negative antibodies for
OAC, and a positive expression of mCEA in the meta-
static neoplastic cells argues against such diagnosis. It is
worth noting that this stands true only for the serous type
and that mucinous ovarian adenocarcinomas can be posi-
tive for mCEA and negative for WT-1. In addition, our
findings revealed that there is a much higher expression
of mCEA in LAC than BAC.
To date, there are no specific markers of ovarian adeno-
carcinoma which is one of the most common neoplasms
to present with ascites.11,12 CA125 is a glycoprotein iden-
tified on the cell membrane in celomic epithelium during
embryogenesis, expressed in a high percentage of ovarian
carcinomas. More than 90% of ovarian cancers and 10–30%
of primary breast cancers have been reported to express
CA125.15 The expression of CA125 has also been
detected in tissue sections of numerous other tumors,
including those of lung, stomach, pancreas, and mesothe-
lium, limiting its diagnostic value.12–15 Our study showed
that CA125 was expressed in 20/20 OCA cases (100%)
with a characteristic membranous staining pattern, rim-
ming around the tumor cell aggregates as compared with
8/13 (61.5%) of metastatic lung cancers and 6/13 (46%)
of metastatic breast cancers. CA125 demonstrates a typi-
cally strong and diffuse pattern in metastatic ovary and
breast carcinomas, in contrast with a relatively focal stain-
ing pattern in the metastatic lung carcinoma.
In conclusion, positive immunoreactivity for WT1 and/
or CA125 with a negative reaction to CEA would be sup-
portive of an OAC particularly in a peritoneal fluid. A
positive CEA argues against the diagnosis of OAC of the
serous type. In the event of a positive CEA, TTF-1 would
be useful in confirming a LAC particularly in a pleural
fluid (Fig. 1). BAC is less likely to express CEA and
WT-1 than LAC.
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